Xenon Pharmaceuticals XENE Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -37.5%-5.9pp | -51.8%-23.9pp | -45.1%-15.4pp | -37.6%-10.9pp | -31.6%-7.6pp | |
| Return on assets | -36%-5.7pp | -48.3%-21.8pp | -42.4%-14.1pp | -35.7%-10.3pp | -30.3%-7.2pp | |
| Return on invested capital | -59.1%-18.3pp | -73.7%-34.2pp | -57.6%-17.3pp | -52%-15.7pp | -40.8%-10.3pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×— | 0×— | 0×— | 0×— | |
| Liquidity | ||||||
| Current ratio | 27.8×+10.1× | 13.4×-4.4× | 12.5×-9.7× | 15.1×-8.1× | 17.7×-14.2× | |
| Quick ratio | 27.8×+10.1× | 13.4×-4.4× | 12.5×-9.7× | 15.1×-8.1× | 17.7×-14.2× | |
| Cash ratio | 13.7×+10.1× | 4.8×+0.8× | 2.7×-0.2× | 4.1×-0.3× | 3.6×+1.0× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $15.32+71.2% | $7.34-24.3% | $7.06-31.0% | $8.03-26.1% | $8.95-21.8% | |
| Valuation | ||||||
| Market capitalization | $5.55B+116% | $3.46B+15.9% | $3.1B+1.2% | $2.47B-18.4% | $2.57B-14.7% | |
| Enterprise value | $5.01B+104% | $3.27B+14.6% | $3B+0.7% | $2.34B-19.2% | $2.46B-17.0% | |
| Price / book | 4.1×+0.5× | 6×+2.0× | 5.5×+1.7× | 3.9×+0.3× | 3.6×+0.3× | |
| Free cash flow yield | -5.5%+2.2pp | -8.1%-1.9pp | -8.2%-2.8pp | -9.4%-4.0pp | -7.8%-2.3pp | |
| Earnings yield | -6.9%+2.9pp | -10%-2.1pp | -9.9%-2.9pp | -11.3%-4.7pp | -9.8%-3.5pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Xenon Pharmaceuticals's ratios come from?
- Every ratio is computed from Xenon Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.